PurposeNoninvasive assessment of liver fibrosis holds significant clinical importance. We aimed to evaluate the clinical potential of using a continuous-time random-walk diffusion model (CTRW) for staging liver fibrosis. MethodsThis prospective study included 52 patients suspected of liver disease and scheduled for liver biopsy. All patients underwent multi-b value diffusion-weighted imaging (DWI) using a 1.5 T MR scanner to derive the anomalous diffusion coefficient (D) and temporal (α) and spatial (β) diffusion heterogeneity indexes sourced from the CTRW. The mono-exponential DWI-derived apparent diffusion coefficient (ADC), transient elastography-derived liver stiffness measurement (LSM), aspartate aminotransferase-to-platelet ratio index (APRI), and fibrosis-4 (FIB-4) index were calculated. We assessed and compared the correlations of these parameters with fibrosis stages and their efficacy in staging liver fibrosis. ResultsSignificant correlations with fibrosis stages were found for APRI (r = 0.336), FIB-4 (r = 0.351), LSM (r = 0.523), D (r = −0.458), and ADC (r = −0.473). Significant differences were observed between APRI, LSM, D, and ADC of different fibrosis stages. The diagnostic performance of an index that combined D, α, β, ADC, and LSM was superior to that of ADC or LSM alone for fibrosis stage F ≥ 2 and better than the index that combined D, α, β for fibrosis stage F ≥ 4. ConclusionsAccurate liver fibrosis staging was achieved with a model that combined CTRW-derived parameters (D, α, and β), ADC, and LSM. The model could serve as a reliable tool for noninvasive fibrosis evaluation.